Abstract: Objective:To detect the methylation of CDH13 gene in patients with acute myeloid leukemia(AML),and explore the relationships with clinical features and prognosis of AML patients.Methods:The methylation status of CDH13 promoter gene in bone marrow from 34 patients with AML(AML group) and 22 nonmalignant tumor patients with iron deficiency anemia(control group) were detected using the methylation specific polymerase chain reaction(PCR).The expressions of CDH13 mRNA in two groups were detected using semi-quantitative reverse transcription PCR.All patients were followed-up for 2 years,and the overall survival time of patients were calculated.Results:The CDH13 gene methylation positive rate of AML group(61.76%) was higher than that of control group(27.27%)(P<0.05).The relative content of CDH13 mRNA in AML group(0.355±0.109) was significantly lower than that in control group(0.745±0.271)(P<0.01).The differences of the methylation status of CDH13 gene in AML patients of indifferent gender,age and clinical typing were not statistically significant(P>0.05).Kaplan-Meier survival curve analysis showed that the overall survival time in AML patients with positive methylation of CDH13 gene(12.4±3.3)months was significantly shorter than that in AML patients with negative methylation of CDH13 gene(18.6±4.1) months(P<0.01).Conclusions:The methylation phenomenon of CDH13 gene can be found in patients with AML,and detecting the CDH13 gene expression can help to judge the prognosis of patients.